Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
| Revenue (TTM) | $11.56B |
| Gross Profit (TTM) | $3.84B |
| EBITDA | $2.27B |
| Operating Margin | 15.20% |
| Return on Equity | 14.60% |
| Return on Assets | 6.40% |
| Revenue/Share (TTM) | $105.09 |
| Book Value | $68.33 |
| Price-to-Book | 3.52 |
| Price-to-Sales (TTM) | 2.26 |
| EV/Revenue | 2.784 |
| EV/EBITDA | 14.28 |
| Quarterly Earnings Growth (YoY) | 15.00% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $110.37M |
| Float | $109.80M |
| % Insiders | 0.44% |
| % Institutions | 98.98% |
Volatility is currently expanding
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.
Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humanity Biological Age add-on when purchasing select health profile tests from questhealth.com including Elite Health Profile, Men's and Women's Comprehensive Health Profiles, and Fitness Profile — Elite, with no additional blood draw needed.
SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m.
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DGX and any ticker you trade — then tracks every position and per-strategy win rate.
